Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Pediatr Allergy Immunol. 2020 Feb;31 Suppl 24:34-36. doi: 10.1111/pai.13152.
Antihistamines are currently one of the most commonly administered drugs in children. They are used to treat symptoms that depend on histamine release, namely allergic diseases, such as rhinitis, asthma, urticaria, and anaphylaxis. It is possible to distinguish first- and second-generation antihistamines. Pharmacological effects and therapeutic indications are similar, but second-generation antihistamines have fewer adverse effects because they are more selective for peripheral H1 receptors. Although they have been on the market for several years, there are still many adverse effects linked to the antihistamine safety profile, especially in the first years of life. Thus, many antihistamines are prescribed off-label, especially in children younger than 2 years of age, which is the age-group where most of the data on drug safety are lacking and many antihistamines are not recommended. This article aims to provide a practical update on the use of antihistamines in children.
抗组胺药是目前儿童中最常用的药物之一。它们用于治疗依赖于组胺释放的症状,即过敏疾病,如鼻炎、哮喘、荨麻疹和过敏反应。可以区分第一代和第二代抗组胺药。药理作用和治疗指征相似,但第二代抗组胺药的不良反应较少,因为它们对周围 H1 受体更具选择性。尽管它们已经上市多年,但抗组胺药的安全性仍存在许多不良反应,尤其是在生命的最初几年。因此,许多抗组胺药被超适应证使用,尤其是在 2 岁以下的儿童中,这个年龄段缺乏大多数药物安全性数据,许多抗组胺药不被推荐使用。本文旨在提供儿童抗组胺药使用的实用更新。